Elevated IMR (>32), STEMI
Conditions
Keywords
STEMI, IMR, microcirculation, microvascular obstruction, myocardial infarction, physiology, angioplasty, PCI, thrombolysis treatment, thrombolysis
Brief summary
Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery with a balloon (angioplasty) and a small mesh tube (stent) although life saving can cause this clot to break up and get washed downstream, which can make the heart attack worse. The investigators can measure the amount of damage caused to the microcirculation by calculating the IMR (Index of Microcirculatory resistance). This can be measured by a wire in the coronary artery with a pressure sensor at the tip. If the IMR is elevated, it is suggestive of extensive microcirculatory damage. A clot dissolving medicine can be administered in the artery to try and reduce the IMR which can reduce damage to the heart muscle and improve outcomes. Impaired microcirculatory perfusion in patients as a result of ST-elevation myocardial infarction (STEMI) is associated with poor clinical outcomes. This project seeks to identify patients with impaired microcirculatory perfusion after STEMI and to assess whether acute improvement in microcirculatory perfusion in these patients by the use of intracoronary thrombolytic therapy results in improved clinical outcomes.
Detailed description
Patients presenting to the participating hospitals with a heart attack will be approached to participate in the study. After angioplasty has been performed, the IMR will be measured in the infarct related artery. If the IMR is \>32 patients will be randomised to receive intracoronary clot dissolving therapy in the form of low dose tenecteplase (TNK) or water as a placebo. Patients who have an IMR ≤32 will be followed up in a registry. Cardiac enzymes will be measured at baseline and discharge. Randomised participants will receive a cardiac MRI at discharge (3-7 days post primary PCI) and at 6 months post PCI. All participants will be followed up at 30 days, and 6, 12 and 24 months following discharge.
Interventions
DRUGTenecteplase (1/3 systemic weight based dose)
50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
OTHERSterile water for injection (WFI)
Placebo comparative arm.
Sponsors
University of Sydney
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All parties involved will be blinded.
Intervention model description
Multi-Centre double-blind, placebo controlled randomised phase IIIb clinical trial, stratified and balanced between groups on important prognostic factors.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult men and women aged over 18 who present with STEMI within 6 hours of symptom onset. Patients will be eligible if they have symptoms consistent with myocardial ischaemia (chest pain, dyspnoea) for at least 20 minutes accompanied by definite ECGs indicating STEMI as defined by Australian National Heart Foundation (NHF) guidelines 2. Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances 3. Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study 4. (At time of PCI) Patient has received metallic drug-eluting stent 5. Participant consents to have a 3-7 day (discharge) and 6 month follow up cardiac MRI
Exclusion criteria
At the time of screening and/or prior to randomisation, no known; 1. Previous coronary bypass grafting 2. Other residual lesions with ≥50% diameter stenosis in the culprit vessel 3. Prior myocardial infarction in the target territory 4. Presence of contraindications to thrombolytic therapy (including history of stroke and recent brain surgery active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension) 5. Presence of contraindications to adenosine infusion for IMR measurement including sinus node disease, moderate to severe bronchoconstrictive disease and second or third-degree atrioventricular (AV) block 6. Diagnosis of metastatic disease 7. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety 8. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol 9. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception. 10. Participation in any investigational study in the previous 30 days Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the number of participants who experience cardiovascular mortality and rehospitalisation for heart failure at 24 months in those given tenecteplase with those given placebo (Cardiac MRI cohort only) | 24 months | Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review. |
| To compare MI size as a % of LV mass and intramyocardial bleeding rates in participants at 6 months post PCI in those given low dose tenecteplase with those given placebo. | 6 months after primary PCI procedure. | MI size and intramyocardial bleeding rates will be assessed upon cardiac MRI at discharge (3-7 days post procedure) as a baseline measure, and at 6 months post-PCI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of stroke events | 24 months after primary PCI procedure | Stroke events will be assessed by medical record review. Assessment will cover all aspects of the stroke event (including type, severity, frequency). |
| Occurrence of major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium | 24 months after primary PCI procedure | Major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium. Assessed by medical record review. |
| Index of Microcirculatory Resistance (IMR) | 0-2 hours | Index of microcirculatory resistance (IMR) measurement assessed by coronary pressure wire data output review. This is a simple unit scale, with a higher number indicating a worse outcome with a score of more than 25 indicating abnormal microcirculatory function in the heart. |
| Coronary Flow Reserve (CFR) | 0-2 hours | Coronary Flow Reserve measurement assessed by coronary pressure wire data output review, prior to randomisation and immediately after primary PCI. |
| Wall Motion Score | 0-6 months | The score is measured by simple unit scale (1 = normal, 2 = hypokinetic (muscle impaired), 3= akinetic (muscle dead)). Each of the 16 segments of the hearts is scored, with the total being divided by 16 to derive the score. |
| Left ventricular ejection fraction (LVEF) | 0-6 months | Left ventricular ejection fraction measurement from echocardiogram will be used to assess cardiac function prior to randomisation, 48 hours and 6 months post primary PCI |
| Myocardial Blush Grade | 0-2 hours | Myocardial Blush Grade measurement from angiogram will be used to assess cardiac function. The score goes from 0 to 3, with 3 being normal and 0 being absence of myocardial blush |
| TIMI Myocardial Perfusion Grade | 0-2 hours | Thrombolysis in myocardial infarction score from angiogram will be used to assess myocardial perfusion. This score goes from 0 to 3, 3 indicates normal flow within the artery and 0 indicates a complete coronary occlusion. |
| TIMI corrected frame count | 0-2 hours | Thrombolysis in myocardial infarction score with corrected frame count from angiogram to assess myocardial perfusion |
| Cardiac enzyme measurements | 0-32 hours | Cardiac enzyme levels including troponin T, creatine kinase, creatine kinase-MB and high sensitivity troponin T, from blood samples collected during the hospitalisation period (prior to primary PCI and at 8, 16, 24 and 32 hours post primary PCI). |
| Fractional Flow Reserve (FFR) | 0-2 hours | Fractional Flow Reserve measurement assessed by coronary pressure wire data output review prior to randomisation and immediately after primary PCI |
| Number of participants who experience individual components of the primary endpoint: (a) cardiovascular mortality at 24 months, (b) rehospitalisation for heart failure at 24 months; | 24 months after primary PCI procedure | Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review, respectively. |
| Number of Major Adverse Cardiac Events (MACE) | 24 months after primary PCI procedure | Major Adverse Coronary Events (these are combination events involving cardiovascular death, non-fatal MI, non-fatal stroke and unstable angina) assessed from physical assessment and medical record review |
| All-cause mortality | 24 months after primary PCI procedure | All-cause mortality assessed by physical assessment and medical record review. |
| Number of incidences of bailout treatment use for no-reflow syndrome | 24 months after primary PCI procedure | Use of Bailout treatment for no-reflow syndrome assessed by medical record review |
Other
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory markers (Subject to funding) | 0-6 months | Samples of whole blood will be used for inflammatory marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Angiogenic markers (Subject to funding) | 0-6 months | Samples of whole blood will be used for angiogenic marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Liver function (Subject to funding) | 0-6 months | Samples of whole blood will be used for liver function analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Thyroid Function (Subject to funding) | 0-6 months | Samples of whole blood will be used for thyroid function analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Lipid profile (Subject to funding) | 0-6 months | Samples of whole blood will be used for lipid profile analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Lipoprotein profile (Subject to funding) | 0-6 months | Samples of whole blood will be used for lipoprotein profile analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| MicroRNA analyses (Subject to funding) | 0-6 months | Samples of whole blood will be used for microRNA analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| DNA analyses (Subject to funding) | 0-6 months | Samples of whole blood will be used for DNA analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
| Vasoactive markers (Subject to funding) | 0-6 months | Samples of whole blood will be used for vasoactive marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). |
Countries
Australia, New Zealand
Contacts
Primary ContactMartin Ng, MBBS (Hons)
Backup ContactRebecca Mister
Outcome results
None listed